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Introduction
Studies in animal models and observations in human pancreatic tissue indicate that β-cell mass is not static but dynamic and can adapt to changes in insulin demand [1, 2] . Maintenance of functional β-cell mass is important in light of the pathogenesis of type 2 diabetes where increasing peripheral insulin resistance leads to an increasing demand for insulin, which is compensated in the early stages by a corresponding expansion in β-cell mass [3] . As the β-cells eventually fail to compensate and even recess in the face of chronic hyperglycaemia, diabetes ensues. Therefore, it is important to identify factors or pathways which prompt proliferation of β−cells or decrease apoptosis in order to maintain an adequate capacity for insulin secretion.
Increases in β-cell mass may occur via proliferation, cellular growth and/or reduced cell death. Although β-cell number increases mainly by neogenesis during embryonic and foetal life, a small fraction of adult β-cells is able to undergo cell division and can be recruited to reenter the cell cycle [4] . Changes in β-cell size (hypertrophy) have also been reported [5, 6] . On the other hand, a decrease in functional β-cell mass, as observed in type 2 diabetes, is believed to depend on apoptosis and to be induced by a combination of humoral and autocrine factors.
It has been shown that both chronically elevated concentrations of D-glucose as well as increased concentrations of saturated free fatty acids (FFA) like palmitic acid induce β-cell apoptosis [7, 8, 9, 10] . Both of these factors are likely to play a role in the transition to the diabetic state in insulin resistant individuals.
Numerous studies have indicated that signal transduction through the insulin/IGFreceptor pathway is involved in the regulation of β-cell mass and function (for review see [11] ). Insulin and insulin-like growth factor-1 (IGF-1) are growth factors for β-cells and their receptors use IRS proteins for signal transmission [12] . The role of these important signalling components for β-cell growth and function has been studied in knock out mice as well as in β-cell-derived cell lines (for review see [13] ). Mice deficient for Irs1 display insulin resistance in muscle and fat but never develop diabetes because of compensatory expansion of β-cell mass [14, 15] . On the other hand, Irs2 deficient mice develop diabetes at 3-6 weeks [16] or 10 weeks [17] of age because of their inability to compensate for insulin resistance in the liver.
Such mice show loss of β-cell mass and a reduction of insulin content indicating, that Irs2 but not Irs1 is required for maintenance of β-cell mass and function. Loss of Irs3 or Irs4 did not significantly affect glucose homeostasis [18, 19] . Recently, it was found that β-cell-specific expression of IRS2 increases β-cell survival and prevents diabetes in Irs2 -/-mice [20] .
Since β-cell-specific Irs2 knockout mice are not yet available, secondary effects on the regulation of β-cell mass can not be ruled out. In addition, it is not clear at this point if IRS2 is also sufficient to induce proliferation in β-cells ex vivo. To answer these questions, we have used monolayers of cultured isolated islets [21] to study β-cell proliferation and apoptosis.
We have determined the number of proliferating β-cells in isolated rat islets after overexpression of IRS2 or GFP under the control of the cytomegalovirus (CMV) promoter.
We also determined the proliferation rate of a β-cell line (INS-1) after anti-sense RNAmediated downregulation of IRS2. In addition we asked, whether overexpression of IRS2 can protect β-cells from high D-glucose-and free fatty acid-induced apoptosis. Finally, we determined β-cell functionality by measuring insulin secretion in perifusion experiments with islets that overexpressed IRS2. Rat islets: isolation, adenoviral gene transfer and culture with free fatty acids. Islets were isolated from adult male Sprague-Dawley rats (200-250 g) according to Gotoh et al [22] .
Materials and Methods

Generation
Briefly, the common pancreatic duct was ligated where it enters the duodenum and injected with 10 ml cold Hanks' Balanced Salt Solution (HBSS) containing 0.17 g of Liberase (Boehringer Mannheim, Germany), 0.1 mg/ml of DNAse I (Boehringer Mannheim, Germany) and 0.02 M HEPES, pH 7.4. Pancreata were removed and digested in a shaking water bath at 37°C for 20 min. The digestion was stopped with HBSS containing 10 % foetal calf serum (v/v, FCS, Invitrogen, USA) instead of Liberase followed by filtration through cheese cloth.
The islets were separated from the digested pancreas by centrifugation (20 min at 1200 rpm) through a discontinuous Histopaque 1077 (Sigma, USA) gradient, washed with RPMI-1640 medium (Invitrogen, USA), and cultured in 2 ml of RPMI-1640 medium (11.1 mM Dglucose) containing 100 U/ml penicillin, 100 µg/ml streptomycin, 40 µg/ml gentamicin, and 10% (v/v) FCS on 35 mm plates coated with extra-cellular matrix (ECM) derived from bovine corneal endothelial cells (Novamed, Israel) at 37 °C, 5 % CO 2 .
After 24 hours of incubation, when most islets began to flatten, the medium was changed to fresh RPMI-1640 medium (11.1 mM D-glucose) and exposed for 24 hours to 2 x 10 6 pfu of adenovirus. Infectivity was monitored using adenovirus encoding GFP. For incubation with Quantification of β-cell proliferation. Islets on ECM plates were washed with phosphate buffered saline (PBS) and fixed with 4 % paraformaldehyde for 30 min at room temperature, followed by permeabilization with 0.5 % Triton X-100 in PBS for 4 min at room temperature.
Fixed islets were incubated in blocking solution (Histostain Plus Kit, Zymed, USA) for 30 min at room temperature and β-cell proliferation was determined using an antibody against Ki-67 nuclear antigen (expressed during G1, G2, M and S phases of the cell cycle, [24] ).
Mouse monoclonal anti-Ki-67 antibody (Zymed, USA) was added to the islets at a dilution of 1:10 in PBS for 30 min at 37 °C in a moist chamber. For human islets, a prediluted monoclonal mouse anti-human Ki-67 antibody (Zymed, USA) was used. Subsequently, the islets were washed three times with PBS and signals were detected using the Histostain-Plus Kit (Zymed, USA). Co-staining for insulin was done using a guinea pig anti-insulin antibody diluted 1:50 (Dako, USA) for 30 min at 37 °C, followed by a 10 min incubation with a 1:10 dilution of fluorescein-conjugated rabbit anti-guinea pig secondary antibody (Dako, USA). β-cells positive for Ki-67 were counted and expressed as number of proliferating β-cells per total number of β-cells. Scion Image software (Scion Corporation, USA) was used to assess islet size and care was taken to score islets of similar sizes.
Quantification of β-cell apoptosis. β-cell apoptosis was determined using the terminal deoxynucleotidyltransferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay [25] .
Briefly, after the islets were fixed and washed, cell death was detected by enzymatic in situ labeling of DNA strand breaks using the In Situ Cell Death Detection Kit AP (Boehringer Immunofluorescence was detected with a Zeiss fluorescence microscope (Axiolab).
Cell culture. INS-1 cells (gift from C. Wolheim, University of Geneva, Switzerland) were maintained in RPMI-1640 medium containing 11 mM D-glucose supplemented with 10 % (v/v) heat inactivated FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 50 μg/ml gentamycin, 1 mM sodium pyruvate, 10 mM HEPES (pH 7.3) and 50 μM β-mercaptoethanol, at 37° C, under 5 % CO 2 in a humidified atmosphere. CHO-IR cells (obtained from J. E. Pessin, University of Iowa, USA) were maintained in F12 medium (Invitrogen, USA) containing 10 % (v/v) FCS, 100 U/ml penicillin, 100 mg/ml streptomycin.
HEK293 cells were cultured in DMEM-H medium (Invitrogen, USA) containing 10 % FCS, 100 U/ml penicillin, 100 mg/ml streptomycin.
Downregulation of IRS2 expression using antisense RNA. 21 nt RNAs corresponding to rat
Irs2 were chemically synthesised (Microsynth GmbH, Switzerland). Sequences used are 5'-UCC CUC CCU GCG UCC UCU CdTT (sense) and 5'-GAG AGG ACG CAG GGA GGG AdTT (antisense). We originally planned to use dsRNA [26] Islet perifusion. Perifusions were performed essentially as described by [27] . In brief, groups of 100 islets were cultured for 12 hours followed by transfection with adenoviral constructs.
Islet mass was kept constant between the groups. After further culture for 72 hours, islets were loaded onto nylon filters (Brandel Suprafusion) and perifused in a Krebs-Ringer bicarbonate (KRB) buffer at a flow rate of 0.4 ml/minute for 90 minutes in 2.8 mM D-glucose to establish basal insulin secretory rates. Thereafter, islets were perifused with 20 mM Dglucose for 60 minutes followed by 2.8 mM D-glucose for 60 minutes. Perifusate solutions were prewarmed to 37°C. Fractions of 1 ml were collected and insulin content was determined by radioimmunoassay (RIA, CIS Bio International, Gif-Sur-Yvette, France). 
Results
Transfection with adenovirus and overexpression of IRS2 in rat pancreatic islets cultured in suspension and on ECM plates. We used an adenovirus-based vector system with the cytomegalovirus promoter to drive high-level expression of IRS2 in isolated islets. In order to assess the potency of the system, we used a polyclonal anti-IRS2 antibody to determine levels Adv-GFP. Since human β-cells showed a very low proliferation rate in our isolations we were unable to obtain statistically significant results with the limited number of available human donors. Therefore, we used rat islets for our experiments. As shown in Fig. 2 antisense RNA specific for Irs2 reduced IRS2 expression five days after transfection by 70 % (Fig. 4B, lane 4) . The complementary oligonucleotide corresponding to the sense strand or transfection without RNA were used as controls and had no effect on IRS2 expression (Fig.   4B , lanes 2 and 1, respectively). Thymidine incorporation following transfection with the antisense oligonucleotides was decreased 2-fold as compared to untransfected cells or to cells after transfection with sense oligonucleotide (Fig. 4A ).
IRS2 overexpression protects human β-cells from D-glucose-induced apoptosis.
As demonstrated earlier [7, 8] 
Overexpression of IRS2 in isolated rat islets increases insulin secretion. The influence of
high-level expression of IRS2 or IRS1 on insulin secretion was determined in perifusion experiments ( Fig. 7A and B) . As control, islets were transfected with Adv or were left untreated. Perifusion after a total culture period of 94 hours showed biphasic insulin secretion.
Islets overexpressing IRS2 secreted significantly more total insulin (1.58±0.14 fold, p<0.05)
as compared to treatment with Adv (Fig. 7B) 
Discussion
Our findings in human and rat pancreatic islets provide evidence that IRS2 is pivotal for the maintenance of β-cell mass both by inducing proliferation of β-cells and protecting them from glucotoxicity. The role of IRS2 in β-cell proliferation has been studied previously, and it was found that IGF-I increases proliferation in the insulinoma-derived cell line INS-1 via IRS2 [28] . On the other hand, mice deficient for IRS2 show mild β-cell deficiency already at birth. Such mice are unable to expand β-cell mass to compensate for insulin resistance and develop diabetes [16] . This phenotype implies a requirement for IRS2 in the regulation of β-cell mass during embryogenesis. A later requirement for IRS2 in the adult can not be deduced from these animals because of possible secondary effects of the systemic knock-out of the Irs2 gene. Furthermore, because tissue-specific knock-out mice are not yet available the question about autonomy remains unanswered as well. With our study we present evidence for a cell autonomous and instructive (and not only permissive) role of IRS2 in the control of β-cell mass (Fig. 2) . Nevertheless, final proof for autonomy requires a transgene that directs IRS2 expression under a constitutive, β-cell-specific promoter. Therefore, it remains possible that proliferation of β-cells was dependent on expression of IRS2 in other islet cell types. We believe, however, that chances are low for such inductive events because insulin staining indicates that islets from our preparations consist to more than 90 % of β-cells (Fig. 2) . With respect to the question of when IRS2 function is required in β-cells our results support the view that IRS2 is continuously required for proliferation. When we repressed Irs2 in INS-1 cells by antisense RNA oligonucleotides we found a 2-fold reduction in proliferation as determined by thymidine incorporation assays (Fig. 4) . On the other hand, high-level expression enhanced β-cell proliferation in differentiated islets in vitro and therefore IRS2 was capable to bring β-cells into the cell cycle at this stage. It is important to note that, although IRS2 was overexpressed in all β-cells after transfection of islets, not all β-cells entered the cell cycle (Fig. 1B) . This might be due to differences in expression levels or a superimposed mechanism must exist that limits the number of β-cells that can proliferate per islet and IRS2 is not able to override this control in our experimental system.
Chronically elevated D-glucose concentrations have been shown to induce β-cell apoptosis in human islets while palmitate induces β-cell apoptosis in rats and humans. Two different pathways are known to be involved: D-glucose induces apoptosis through the Fas pathway [8, 29] leading to activation of caspase-8. Palmitic acid activates the mitochondrial pathway and involves caspase-9 [9] . Overexpression of IRS2 in human or rat islets protected β-cells from D-glucose-but not from palmitic acid-induced apoptosis ( Fig. 5 and 6 ). The finding in human islets indicates that there is cross-talk between IRS2-dependent signalling and the Fas pathway. Maedler et al. [30] have shown that sufficiently high levels of FLIP(L) (long isoform of FLIP generated by alternative splicing) in β-cells are required to protect against the toxic effect of chronic hyperglycaemia and to attenuate Fas signalling. It is therefore tempting to speculate that IRS2 is a positive regulator of FLIP. We are currently testing this possibility by studying the expression of FLIP in human islets that overexpress IRS2. It was shown that activation of Akt/PKB plays an important role in preventing free fatty acid-induced apoptosis in INS-1 cells [31] . However, overexpression of IRS2 in isolated rat islets did not protect β-cells from palmitic acid-induced apoptosis (Fig. 6) , although Akt/PKB can be a downstream target of IRS2 signalling. Therefore, transfection of isolated rat islets with Adv-IRS2 in the presence of 0.5 mM palmitic acid might not lead to activation of Akt/PKB. Unfortunately, we were not able to detect any form of Akt/PKB in our lysates so far (not shown).
It is well established that short term exposure of rat and human islets to D-glucose causes proliferation of β-cells [32, 8, 33] . In contrast, human islets cultured in vitro for extended periods of time in the presence of high D-glucose display enhanced β-cell apoptosis and a reduced proliferation rate [7, 29] . By overexpressing IRS2 in human islets we were able to completely block the pro-apoptotic effect of chronic high D-glucose on human β-cells.
Moreover, when we cultured human islets for 3 days with 33. Overexpression of IRS2 but not IRS1 increased basal and D-glucose-induced insulin secretion in isolated rat islets after a culture period of 94 hours. However, IRS2 was not effective when we used freshly isolated islets which had been transfected for six hours (data not shown) indicating that the underlying mechanism does not act immediately. An increase in basal insulin secretion could be caused by an increased sensitivity of β-cells to D-glucose.
It was shown that β-cells of transgenic mice expressing higher levels of IRS2 under the control of the rat insulin promoter contained three times more Glut2 than controls [20] . Such an IRS2-induced increase in Glut2 is expected to require time because it probably involves transcriptional control by pdx1 [35] . As a consequence, IRS2 could indeed increase the sensitivity of β-cells to D-glucose resulting in elevated basal insulin concentrations. Such a basal increase can probably not be detected in vivo because the concentration of D-glucose in circulation changes in response to the insulin concentration. However, an increase in the sensitivity of β-cells to D-glucose is expected to improve islet performance in vivo [20] .
In conclusion, we provide evidence for an autonomous role of IRS2 in β-cells. 
